6. Gangadaran, et al. Interleukin-4 Receptor Targeting Peptide Decorated Extracellular Vesicles as a Platform for In Vivo Drug Delivery to Thyroid Cancer. Biomedicines, 2022. 7. Kim, J. E., et al. Engineering of anti-human interleukin-4 receptor alpha antibodies with potent antagonistic activity...
研究者推断IL-4Rα信号调节巨噬细胞极化依赖于肝内微环境情况,所以药物靶向巨噬细胞极化需要根据不同疾病分期进行特异化治疗策略。 原文链接:Weng SY, Wang X, Vijayan S, et al. IL-4 Receptor Alpha Signaling through Macrophages Diffe...
IL-4受体α阻断剂抑制过敏性炎症并上调IL17A表达以促进抗原致敏小鼠皮肤中金黄色葡萄球菌的清除 IL-4 receptor alpha blockade dampens allergic inflammation and upregulates IL-17A expression to promote S aureus clearance in antigen...
Interleukin-4 Receptor Targeting Peptide Decorated Extracellular Vesicles as a Platform for In Vivo Drug Delivery to Thyroid Cancer. Biomedicines, 2022. 7. Kim, J. E., et al. Engineering of anti-human interleukin-4 receptor alpha antibodies with potent antagonistic activity. Scientific reports, ...
Recombinant Human Interleukin-4 Receptor Subunit Alpha产品规格:10μg|50μg|500μg|1mg发货周期:1～3天产品价格:询价本产品仅可用于科研实验,严禁用于其他非科研用途!本品由我们的哺乳动物细胞表达系统制备而成,目的基因编码的Met26-Gln231在C端带有Fc标签。
BALB/c mice, susceptibility to infection with the intracellular parasite Leishmania major is driven largely by the development of T helper 2 (Th2) responses and the production of interleukin (IL-4 and IL-13), which share a common receptor subunit, the IL-4 receptor alpha chain (IL-4Rα)...
3.Ramona Hurdayal, Frank Brombacher, Interleukin-4 Receptor Alpha: From Innate to Adaptive Immunity in Murine Models of Cutaneous Leishmaniasis, Front Immunol. 2017 Nov 10;8:1354. 4.Hani Harb, Talal A Chatila, Mechanisms of Dupilumab, Clin Exp Allergy. 2020 Jan;50(1):5-14. ...
6. Gangadaran, et al. Interleukin-4 Receptor Targeting Peptide Decorated Extracellular Vesicles as a Platform for In Vivo Drug Delivery to Thyroid Cancer. Biomedicines, 2022. 7. Kim, J. E., et al. Engineering of anti-human interleukin-4 receptor alpha antibodies with potent antagonistic activity...
Rademikibart (CBP-201) is a next-generation IL-4 receptor alpha-targeting antibody. OBJECTIVE: We sought to evaluate rademikibart in adults with moderate to severe atopic dermatitis. METHODS: A total of 226 patients were randomized, double-blind, to subcutaneous rademikibart (300 mg every 2 ...
6. Gangadaran, et al. Interleukin-4 Receptor Targeting Peptide Decorated Extracellular Vesicles as a Platform for In Vivo Drug Delivery to Thyroid Cancer. Biomedicines, 2022. 7. Kim, J. E., et al. Engineering of anti-human interleukin-4 receptor alpha antibodies with potent antagonistic activity...